SCHEMBL1815535

SCHEMBL1815535

Cn1nccc1-c1cc(C(=O)O)no1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
PTPN1 P18031 3/20 0.49
HPGD P15428 2/20 0.48
MAPT P10636 2/20 0.48
RECQL P46063 1/20 0.48
HTT P42858 1/20 0.46
RARA P10276 2/20 0.43
RXRA P19793 2/20 0.43
RARB P10826 1/20 0.43
RARG P13631 1/20 0.43
CDH1 P12830 1/20 0.41
CTNNB1 P35222 1/20 0.41
TCF7L2 Q9NQB0 1/20 0.41
BRD4 O60885 1/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
APOBEC3A P31941 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4406175 0.76 ALDH1A1 (0.54) ALDH1A1PTPN1HPGDMAPTRECQL
SCHEMBL20507228 0.72 HTT (0.68) ALDH1A1PTPN1HPGDMAPTRECQL
SCHEMBL676174 0.72 ALDH1A1 (0.51) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL22619637 0.70 ALDH1A1 (0.59) ALDH1A1PTPN1HPGDMAPTRECQL
SCHEMBL21523605 0.70 ALDH1A1 (0.54) ALDH1A1PTPN1HPGDMAPTRECQL
SCHEMBL21523628 0.70 SCD5 (0.65) ALDH1A1PTPN1HPGDMAPTRECQL
SCHEMBL1816428 0.70 ALDH1A1 (0.54) ALDH1A1PTPN1HPGDMAPTRECQL
SCHEMBL674283 0.70 PDE4B (0.42) ALDH1A1PTPN1KDM4EPOLBGAA
SCHEMBL16834639 0.70 KDM4E (0.48) ALDH1A1KDM4EPOLBGAAAPOBEC3A
SCHEMBL31704800 0.70 KDM4E (0.48) ALDH1A1KDM4EPOLBGAAAPOBEC3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 EP disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 EP disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 EP disclosed
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2020-09-24 US disclosed
US-10711013-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2020-07-14 US disclosed
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2019-04-04 US disclosed
US-10118933-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2018-11-06 US disclosed
EP-3369732-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2018-09-05 EP disclosed
EP-3056485-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2018-05-09 EP disclosed
US-20170260206-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2017-09-14 US disclosed
US-9657003-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2017-05-23 US disclosed
EP-3056485-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2016-08-17 EP disclosed
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION 2015-07-23 US disclosed
US-8975254-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2015-03-10 US disclosed
EP-2493858-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2014-07-02 EP disclosed
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-09-06 US disclosed
EP-2493858-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2012-09-05 EP disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 WO disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260206-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG ALDH1A1 570/4885PTPN1 1057/4885HPGD 704/4885
US-10118933-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG ALDH1A1 570/4885PTPN1 1057/4885HPGD 704/4885
US-10711013-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG ALDH1A1 570/4885PTPN1 1057/4885HPGD 704/4885
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG ALDH1A1 570/4885PTPN1 1057/4885HPGD 704/4885
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG ALDH1A1 570/4885PTPN1 1057/4885HPGD 704/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG ALDH1A1 570/4885PTPN1 1057/4885HPGD 704/4885
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG ALDH1A1 570/4885PTPN1 1057/4885HPGD 704/4885
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG ALDH1A1 570/4885PTPN1 1057/4885HPGD 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.